Weekly cisplatin fails to reduce overall acute toxicity during head and neck chemoradiotherapy
NRG-HN009 found no reduction in overall acute grade 3-4 toxicity with weekly versus three-weekly cisplatin during definitive head and neck RT. Toxicity profiles differed, and neither phase II cohort met the criteria to proceed to phase III.